{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T08:34:52Z","timestamp":1790152492976,"version":"4.0.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,2,9]],"date-time":"2017-02-09T00:00:00Z","timestamp":1486598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1038\/bjc.2017.19","type":"journal-article","created":{"date-parts":[[2017,2,9]],"date-time":"2017-02-09T23:46:17Z","timestamp":1486683977000},"page":"697-702","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["Overall survival and clinical characteristics of BRCA mutation carriers with stage I\/II pancreatic cancer"],"prefix":"10.1038","volume":"116","author":[{"given":"Talia","family":"Golan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Sella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen M","family":"O'Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew H G","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Epelbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P","family":"Kelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayelet","family":"Borgida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Maynard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedy","family":"Kindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eitan","family":"Friedmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milind","family":"Javle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Gallinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,9]]},"reference":[{"key":"BFbjc201719_CR1","unstructured":"NCCN Clinical Practice Guidelines in Oncology\u2013Pancreatic Adenocarcinoma. National Comprehensive Cancer Network. 2016."},{"key":"BFbjc201719_CR2","first-page":"505","volume":"60","author":"D Abeliovich","year":"1997","unstructured":"Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, Heching N, Peretz T (1997) The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 60: 505\u2013514.","journal-title":"Am J Hum Genet"},{"key":"BFbjc201719_CR3","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.ccell.2015.09.020","volume":"28","author":"AV Biankin","year":"2015","unstructured":"Biankin AV, Maitra A (2015) Subtyping pancreatic cancer. Cancer Cell 28: 411\u2013413.","journal-title":"Cancer Cell"},{"key":"BFbjc201719_CR4","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, De La Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817\u20131825.","journal-title":"N Engl J Med"},{"key":"BFbjc201719_CR5","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/(SICI)1097-0215(19960126)65:3<284::AID-IJC2>3.0.CO;2-W","volume":"65","author":"DF Easton","year":"1996","unstructured":"Easton DF, Matthews FE, Ford D, Swerdlow AJ, Peto J (1996) Cancer mortality in relatives of women with ovarian cancer: the OPCS Study. Office of Population Censuses and Surveys. Int J Cancer 65: 284\u2013294.","journal-title":"Int J Cancer"},{"key":"BFbjc201719_CR6","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","volume":"17","author":"SB Edge","year":"2010","unstructured":"Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17: 1471\u20131474.","journal-title":"Ann Surg Oncol"},{"key":"BFbjc201719_CR7","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1200\/JCO.2008.18.5546","volume":"27","author":"CR Ferrone","year":"2009","unstructured":"Ferrone CR, Levine DA, Tang LH, Allen PJ, Jarnagin W, Brennan MF, Offit K, Robson ME (2009) BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol 27: 433\u2013438.","journal-title":"J Clin Oncol"},{"key":"BFbjc201719_CR8","first-page":"1417","volume":"31","author":"DR Fogelman","year":"2011","unstructured":"Fogelman DR, Wolff RA, Kopetz S, Javle M, Bradley C, Mok I, Cabanillas F, Abbruzzese JL (2011) Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. Anticancer Res 31: 1417\u20131420.","journal-title":"Anticancer Res"},{"key":"BFbjc201719_CR9","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1038\/bjc.2014.418","volume":"111","author":"T Golan","year":"2014","unstructured":"Golan T, Kanji ZS, Epelbaum R, Devaud N, Dagan E, Holter S, Aderka D, Paluch-Shimon S, Kaufman B, Gershoni-Baruch R, Hedley D, Moore MJ, Friedman E, Gallinger S (2014) Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer 111: 1132\u20131138.","journal-title":"Br J Cancer"},{"key":"BFbjc201719_CR10","doi-asserted-by":"publisher","first-page":"e476","DOI":"10.1016\/S1470-2045(13)70172-4","volume":"14","author":"W Hartwig","year":"2013","unstructured":"Hartwig W, Werner J, Jager D, Debus J, Buchler MW (2013) Improvement of surgical results for pancreatic cancer. Lancet Oncol 14: e476\u2013e485.","journal-title":"Lancet Oncol"},{"key":"BFbjc201719_CR11","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","volume":"33","author":"B Kaufman","year":"2015","unstructured":"Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmana J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM (2015) Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation. J Clin Oncol 33: 244\u2013250.","journal-title":"J Clin Oncol"},{"key":"BFbjc201719_CR12","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1634\/theoncologist.2011-0185","volume":"16","author":"MA Lowery","year":"2011","unstructured":"Lowery MA, Kelsen DP, Stadler ZK, Yu KH, Janjigian YY, Ludwig E, D\u2019Adamo DR, Salo-Mullen E, Robson ME, Allen PJ, Kurtz RC, O\u2019Reilly EM (2011) An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist 16: 1397\u20131402.","journal-title":"Oncologist"},{"key":"BFbjc201719_CR13","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1007\/s11605-008-0791-5","volume":"13","author":"SA Muller","year":"2009","unstructured":"Muller SA, Hartel M, Mehrabi A, Welsch T, Martin DJ, Hinz U, Schmied BM, Buchler MW (2009) Vascular resection in pancreatic cancer surgery: survival determinants. J Gastrointest Surg 13: 784\u2013792.","journal-title":"J Gastrointest Surg"},{"key":"BFbjc201719_CR14","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/ng1096-188","volume":"14","author":"C Oddoux","year":"1996","unstructured":"Oddoux C, Struewing JP, Clayton CM, Neuhausen S, Brody LC, Kaback M, Haas B, Norton L, Borgen P, Jhanwar S, Goldgar D, Ostrer H, Offit K (1996) The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 14: 188\u2013190.","journal-title":"Nat Genet"},{"key":"BFbjc201719_CR15","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1001\/jama.2013.279201","volume":"310","author":"H Oettle","year":"2013","unstructured":"Oettle H, Neuhaus P, Hochhaus A, Hartmann J, Geller TK, Ridwelski K, Niedergethmann M, Z\u00fclke C, Fahlke J, Arning M, Sinn M, Hinke A, Riess H (2013) Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 310: 1473\u20131481.","journal-title":"JAMA"},{"key":"BFbjc201719_CR16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/ng1096-185","volume":"14","author":"BB Roa","year":"1996","unstructured":"Roa BB, Boyd AA, Volcik K, Richards CS (1996) Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 14: 185\u2013187.","journal-title":"Nat Genet"},{"key":"BFbjc201719_CR17","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1097\/MPA.0b013e318291fbc5","volume":"42","author":"M Worni","year":"2013","unstructured":"Worni M, Guller U, White R, Castleberry A, Pietrobon R, Cerny T, Gloor B, Koeberle D (2013) Modest improvement in overall survival for patients with metastatic pancreatic cancer: a trend analysis using the surveillance, epidemiology, and end results registry from 1988 to 2008. Pancreas 42: 1157\u20131163.","journal-title":"Pancreas"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc201719.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc201719","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc201719.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:38:20Z","timestamp":1684417100000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc201719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,9]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["BFbjc201719"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2017.19","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,9]]},"assertion":[{"value":"6 June 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}